
What are the CAR T-cell therapies on the horizon for lymphoma?
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Pere Barba, Hospital Universitari Vall d'Hebron, Barcelona, ES. We asked, What are the chimeric antigen receptor (CAR) T-cell therapies on the horizon for lymphoma?
Barba summarizes the progress made in the development of second generation CD19 CAR T-cell therapies, dual CAR T-cell therapies, allogeneic CAR T-cell platforms, alternatives to CD19 CAR T-cell therapies, and combining checkpoint inhibitors with conventional CAR T-cell therapies.
Hosted on Acast. See acast.com/privacy for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.